HK1065335A1 - Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture - Google Patents
Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial cultureInfo
- Publication number
- HK1065335A1 HK1065335A1 HK04108196.1A HK04108196A HK1065335A1 HK 1065335 A1 HK1065335 A1 HK 1065335A1 HK 04108196 A HK04108196 A HK 04108196A HK 1065335 A1 HK1065335 A1 HK 1065335A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- protein
- interest
- supernatant
- secretion
- bacterial culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10108212A DE10108212A1 (de) | 2001-02-20 | 2001-02-20 | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
| PCT/EP2002/001307 WO2002068660A1 (en) | 2001-02-20 | 2002-02-08 | Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1065335A1 true HK1065335A1 (en) | 2005-02-18 |
Family
ID=7674913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK04108196.1A HK1065335A1 (en) | 2001-02-20 | 2004-10-20 | Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1364029B1 (xx) |
| JP (1) | JP4243104B2 (xx) |
| KR (1) | KR100858009B1 (xx) |
| CN (1) | CN100500853C (xx) |
| AT (1) | ATE314480T1 (xx) |
| AU (1) | AU2002231784B2 (xx) |
| BR (1) | BRPI0207394B8 (xx) |
| CA (1) | CA2438886C (xx) |
| DE (2) | DE10108212A1 (xx) |
| DK (1) | DK1364029T3 (xx) |
| ES (1) | ES2254658T3 (xx) |
| HK (1) | HK1065335A1 (xx) |
| IL (1) | IL157414A0 (xx) |
| MX (1) | MXPA03007114A (xx) |
| NO (1) | NO331271B1 (xx) |
| NZ (1) | NZ527643A (xx) |
| PE (1) | PE20020876A1 (xx) |
| WO (1) | WO2002068660A1 (xx) |
| ZA (1) | ZA200305869B (xx) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| EP2314602A1 (en) | 2003-11-21 | 2011-04-27 | Pfenex, Inc. | Improved expression systems with SEC-system secretion |
| AU2005206951B2 (en) | 2004-01-16 | 2010-08-19 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| AU2005269527B2 (en) | 2004-07-26 | 2011-12-01 | Pfenex Inc. | Process for improved protein expression by strain engineering |
| DE102006031955A1 (de) * | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| DE102006050332A1 (de) | 2006-10-25 | 2008-04-30 | Wacker Chemie Ag | DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen |
| AU2008210538B2 (en) | 2007-01-31 | 2013-06-06 | Pelican Technology Holdings, Inc. | Bacterial leader sequences for increased expression |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| JP5444553B2 (ja) | 2007-04-27 | 2014-03-19 | フェネックス インコーポレイテッド | 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法 |
| CA2711749A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE102008025008A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| NZ586589A (en) | 2008-01-09 | 2012-04-27 | Sanofi Aventis Deutschland | Novel insulin analogues having an extremely delayed time-action profile |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE102008025007A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| WO2010038145A2 (en) * | 2008-10-02 | 2010-04-08 | Unitargeting Research As | Kit for the optimisation of protein synthesis/secretion |
| LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| PL2498801T3 (pl) | 2009-11-13 | 2018-08-31 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę |
| ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
| HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CN108079281A (zh) | 2011-08-29 | 2018-05-29 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| ES2853935T3 (es) | 2013-03-12 | 2021-09-20 | Massachusetts Gen Hospital | Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades |
| AU2014362307A1 (en) | 2013-12-11 | 2016-06-30 | The General Hospital Corporation | Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation |
| US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341417C (fr) * | 1984-03-27 | 2003-01-21 | Paul Tolstoshev | Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| CA2255396A1 (en) * | 1990-11-08 | 1992-05-09 | Nippon Mining Company Limited | Hirudin analog, method of manufacturing thereof and anti-coagulant composition, and secretion vector, transformed microorganisms containing said vector and manufacturing method ofproducts which is produced from said microorganism |
| CA2128689A1 (en) * | 1992-09-28 | 1995-04-06 | Harold T. Pehr | Kicker latch for container closures |
| DE10033195A1 (de) * | 2000-07-07 | 2002-03-21 | Aventis Pharma Gmbh | Bifunktionale Fusionsproteine aus Hirudin und TAP |
-
2001
- 2001-02-20 DE DE10108212A patent/DE10108212A1/de not_active Withdrawn
-
2002
- 2002-02-06 PE PE2002000081A patent/PE20020876A1/es not_active Application Discontinuation
- 2002-02-08 AU AU2002231784A patent/AU2002231784B2/en not_active Expired
- 2002-02-08 KR KR1020037010943A patent/KR100858009B1/ko active IP Right Grant
- 2002-02-08 DK DK02711847T patent/DK1364029T3/da active
- 2002-02-08 DE DE60208343T patent/DE60208343T2/de not_active Expired - Lifetime
- 2002-02-08 ES ES02711847T patent/ES2254658T3/es not_active Expired - Lifetime
- 2002-02-08 AT AT02711847T patent/ATE314480T1/de active
- 2002-02-08 JP JP2002568754A patent/JP4243104B2/ja not_active Expired - Lifetime
- 2002-02-08 MX MXPA03007114A patent/MXPA03007114A/es active IP Right Grant
- 2002-02-08 CA CA2438886A patent/CA2438886C/en not_active Expired - Lifetime
- 2002-02-08 IL IL15741402A patent/IL157414A0/xx active IP Right Grant
- 2002-02-08 NZ NZ527643A patent/NZ527643A/en not_active IP Right Cessation
- 2002-02-08 EP EP02711847A patent/EP1364029B1/en not_active Expired - Lifetime
- 2002-02-08 BR BRPI0207394A patent/BRPI0207394B8/pt not_active IP Right Cessation
- 2002-02-08 WO PCT/EP2002/001307 patent/WO2002068660A1/en active IP Right Grant
- 2002-02-08 CN CNB028068505A patent/CN100500853C/zh not_active Expired - Lifetime
-
2003
- 2003-07-30 ZA ZA200305869A patent/ZA200305869B/en unknown
- 2003-08-19 NO NO20033673A patent/NO331271B1/no not_active IP Right Cessation
-
2004
- 2004-10-20 HK HK04108196.1A patent/HK1065335A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03007114A (es) | 2003-11-18 |
| ATE314480T1 (de) | 2006-01-15 |
| DE60208343T2 (de) | 2006-06-22 |
| BR0207394A (pt) | 2004-02-10 |
| DE10108212A1 (de) | 2002-08-22 |
| NO20033673D0 (no) | 2003-08-19 |
| NO20033673L (no) | 2003-10-17 |
| NO331271B1 (no) | 2011-11-14 |
| BRPI0207394B8 (pt) | 2021-05-25 |
| KR20030074842A (ko) | 2003-09-19 |
| JP2004518444A (ja) | 2004-06-24 |
| CN1529757A (zh) | 2004-09-15 |
| JP4243104B2 (ja) | 2009-03-25 |
| CN100500853C (zh) | 2009-06-17 |
| ES2254658T3 (es) | 2006-06-16 |
| CA2438886A1 (en) | 2002-09-06 |
| AU2002231784B2 (en) | 2006-10-26 |
| KR100858009B1 (ko) | 2008-09-11 |
| WO2002068660A1 (en) | 2002-09-06 |
| IL157414A0 (en) | 2004-03-28 |
| BRPI0207394B1 (pt) | 2015-06-16 |
| DE60208343D1 (de) | 2006-02-02 |
| EP1364029B1 (en) | 2005-12-28 |
| CA2438886C (en) | 2013-07-23 |
| DK1364029T3 (da) | 2006-05-08 |
| PE20020876A1 (es) | 2002-11-05 |
| EP1364029A1 (en) | 2003-11-26 |
| NZ527643A (en) | 2005-07-29 |
| ZA200305869B (en) | 2004-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1065335A1 (en) | Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture | |
| NZ521396A (en) | Fusion proteins comprising two or more Neisseria polypeptides | |
| EP1470236A4 (en) | PROCESSES AND COMPOSITIONS FOR PROTEIN EXPRESSION AND CLEANING | |
| WO2005003313A8 (en) | Methods and compositions for enhanced protein expression and purification | |
| AU2003239365A1 (en) | Recombinant glycosyltransferase fusion proteins | |
| AU2002367147A1 (en) | Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | |
| AU2002217505A1 (en) | Process for producing recombinant protein and fused protein | |
| AU2001238212A1 (en) | Modified fluorescent proteins | |
| AU2002349231A1 (en) | Methylotrophic bacterium for the production of recombinant proteins and other products | |
| AU2002232803A1 (en) | Expression system for recombinant proteins | |
| AU2003254680A1 (en) | Staphylococcal nuclease fusion proteins for the production of recombinant peptides | |
| WO2006097708A3 (en) | Affinity purification of protein | |
| GB0116460D0 (en) | Biological products | |
| EP1451367A4 (en) | GENE OF LEADING PEPTIDES FOR SECRETING RECOMBINANT PROTEINS IN BACTERIA | |
| AU2002311620A1 (en) | Methods of making and using expression constructs for the expression of recombinant proteins | |
| AU2002356339A1 (en) | Soluble recombinant protein production | |
| AU2003226907A8 (en) | Method for the preparation of recombinant mammalian heparin-binding protein (hbp) | |
| AU2001251132A1 (en) | Expression of uncoupling protein (ucp) in plants | |
| WO2002097042A3 (en) | Chimeric proteins for cell targeting and apoptosis induction and methods of using the same | |
| AU2002317763A1 (en) | Human protein phosphatase 2c-like enzyme | |
| WO2003016465A3 (en) | Cell cycle regulator protein | |
| AU2003255988A8 (en) | Yeast protein expression secretion system | |
| AU2002328222A1 (en) | Purified bacterial polypeptides involved in protein processing | |
| IL204767A (en) | Stable chimeric oligomeric proteins for denture and protease resistant | |
| AU2002330857A1 (en) | Novel proteins and nucleic acids encoding same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |
Effective date: 20220207 |